SASKATOON, Saskatchewan–(BUSINESS WIRE)–CanniMed Therapeutics Inc. (TSX: CMED) proactively commissioned an independent laboratory analysis of the Company’s herbal cannabis products to test for 56 known pesticides, fungicides and PGRs (plant growth regulators). Each analyzed lot returned a clean Certificate of Analysis with “not detected” levels for each of the 56 pesticides, fungicides and PGRs.
“CanniMed Therapeutics has never, and will not in the future need to use pesticides, fungicides or PGRs in the manufacturing of our medical cannabis products because we follow a strict GMP process, following 281-points of quality control,” said Brent Zettl, President and CEO, CanniMed Therapeutics Inc. “By commissioning this evaluation, we looked to demonstrate to patients, physicians and investors how our GMP-compliant production process ensures cleanliness and prevention, resulting in products that can be trusted to be free from all contaminants.”
CMED commissioned Anandia Labs, Canada’s leading cannabis genetics and testing facility founded by internationally-recognized cannabis scientist Dr. Jonathan Page for this important analysis. Four lots of CMED’s proprietary strains (CanniMed® 22.1, CanniMed® 12.0, CanniMed® 9.9 and CanniMed® 1.13) were analyzed and each were awarded a clean Certificate of Analysis.
“Anandia Labs uses highly sensitive LC-MS/MS methods to identify and quantify the main pesticides and PGRs of known concern in cannabis, including myclobutanil, bifenazate and paclobutrazol,” said Dr. Jonathan Page, President and CEO, Anandia Labs. “Our lab has been at the forefront of cannabis-relevant pesticide testing and I am pleased that Anandia Labs was chosen by a leading Licensed Producer such as CanniMed Therapeutics to provide independent testing services to help ensure patient safety.”
About CanniMed Therapeutics Inc.
The Company is a Canadian-based, international plant biopharmaceutical company and a leader in the Canadian medical cannabis industry, with 15 years of pharmaceutical cannabis cultivation experience, state-of-the-art, GMP-compliant plant production processes and world class research and development platforms with a wide range of pharmaceutical-grade cannabis products. In addition, the Company has an active plant biotechnology research and product development program focused on the production of plant-based materials for pharmaceutical, agricultural and environmental applications.
CanniMed Ltd., a wholly-owned subsidiary of the Company, was the first producer to be licensed under the Marihuana for Medical Purposes Regulations, the predecessor to the current Access to Cannabis for Medical Purposes Regulations.
Prairie Plant Systems Inc., a wholly-owned subsidiary of the Company, was the sole supplier to Health Canada under the former medical marijuana system for 13 years, and has been producing safe and consistent medical marijuana for thousands of Canadian patients, with no incident of diversion.
Notice Regarding Forward Looking Statements
This news release contains forward-looking statements within the meaning of applicable securities laws. All statements that are not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, are “forward-looking statements”. Forward-looking statements can be identified by the use of words such as “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved.
Forward-looking statements are based on assumptions and involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of CanniMed Therapeutics Inc. to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including the risks described in CanniMed Therapeutics Inc.’s documents filed with applicable Canadian securities regulatory authorities which may be viewed at sedar.com. The forward-looking statements included in this news release are made as of the date of this news release. CanniMed Therapeutics Inc. does not undertake to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise, unless required by applicable securities legislation.
For more information or to schedule an interview, please contact:
CanniMed Therapeutics Inc.
Dara Willis, 416-836-9272